Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases
Sponsor: Shandong Qilu Stem Cells Engineering Co., Ltd.
Summary
Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment. Thus, how to better prevent such diseases is currently a key research topic in the international field. The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes.
Official title: Efficacy Evaluation of Umbilical Cord Blood-derived Mononuclear Cells in the Treatment of Refractory Neonatal Diseases
Key Details
Gender
All
Age Range
1 Day - 28 Days
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2022-04-01
Completion Date
2025-04-30
Last Updated
2024-05-24
Healthy Volunteers
No
Interventions
Mononuclear cells
UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
Mild hypothermia therapy
Mild hypothermia therapy via hypothermia therapy apparatus
Breathing support technique
Breathing support via ventilator
Total parenteral nutrition
Liquid nutrition injected directly into the bloodstream
Locations (1)
Qilu Children's Hospital of Shandong University
Jinan, Shandong, China